Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Clinical trials with immunotherapy for breast and colorectal cancer

Clinical trials with immunotherapy for breast and colorectal cancer

November 01, 2005

Mount Sinai School of Medicine conducting clinical trials with immunotherapy for breast and colorectal cancer

Researchers at Mount Sinai School of Medicine are conducting clinical trials on a unique approach to enhance the immune system in patients with breast or colorectal cancer. The study uses a potent immune-enhancing gene delivered directly into the cancer cells to make them look foreign to the body's immune system, which will then attack and destroy the cancer.




In experiments with laboratory animals, Mount Sinai researchers have demonstrated that their approach, known as tumor immunization, extended life in all animals tested and wiped out cancer entirely in up to 20-30% of animals whose breast or colorectal cancer had spread. With currently available treatments, the prognosis for patients with breast or colorectal cancer which has spread to other organs, including the liver, is poor.

"Cancer cells are able to grow unimpeded by the body's defenses because they look very similar to healthy cells, with only very subtle differences that pass under the radar screen of the body's immune cells," said Savio Woo, PhD, Professor and Chairman of the Department of Gene and Cell Medicine at Mount Sinai School of Medicine. "We use gene transfer technology to insert an immune enhancing gene into the cancer cells that makes them visible to the body's natural immune defenses."

The method of tumor immunization which Mount Sinai researchers developed involves transferring a gene that codes for Interleukin-12 (IL12) into cancer cells directly in the patient's tumor. IL12 is a potent immune enhancing protein that is not normally produced by cancer cells. When the cancer cells produce this protein as a result of gene transfer it acts as a signal to a special class of white blood cells of the immune system telling them, "These cancer cells are dangerous. Come over here and destroy them."

The laboratory animal studies conducted by Dr. Woo and colleagues have provided evidence that delivering the IL12 gene to cancer cells can trigger a targeted immune response that destroys tumor cells. Their impressive results along with extensive pharmacological and toxicology studies they conducted were sufficient evidence to convince the FDA, NIH and Mount Sinai's Institutional Review Board that the promise of this research is ready to be tested in humans. The first phase of clinical trials to establish the safety of these treatments in patients with breast or colorectal cancer began recently.

Dr. Woo and colleagues developed a disarmed virus that carries the IL12 gene into the cancer cells. "The virus was developed in a special multi-million dollar facility here at Mount Sinai," said Dr. Woo. "This state-of-the-art facility provides us the means to produce a disarmed virus that can not reproduce itself and can not lead to a sustained infection in patients. In animal experiments we have found that this maximizes both effectiveness and safety, and we hope to see the same in humans."

The researchers will use one of the tumors which has spread to the liver as the target for inserting the gene. "The procedure does not require surgery and is done with just local anesthesia to the skin," said Max W. Sung, MD, Medical Director for the Derald H. Ruttenberg Cancer Treatment Center and Associate Professor in Hematology-Oncology at Mount Sinai School of Medicine. "Using one to three needles, the disarmed virus harboring the IL12 gene is injected through the skin into a metastatic tumor in the liver. We perform an ultrasound exam at the same time to track the needles so that we can deliver the virus to the correct location. The entire procedure can be completed within half an hour."

The Mount Sinai Hospital



Related Immunotherapy Current Events and Immunotherapy News Articles Immunotherapy Current Events and Immunotherapy News RSS Immunotherapy Current Events and Immunotherapy News RSS
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

Alzheimer's lesions found in the retina
The eyes may be the windows to the soul, but new research indicates they also may mirror a brain ravaged by Alzheimer's disease.

Elderly immune system needs a boost
Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease.

Oleocanthal may help prevent, treat Alzheimer's
Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.

University Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease
Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.

Mounting a multi-layered attack on fungal infections
Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

Researchers testing virus-gene therapy combination against melanoma
Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease.

Vaccine shows therapeutic promise against advanced melanoma
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2.

New therapy enlists immune system to boost cure rate in a childhood cancer
A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.
More Immunotherapy Current Events and Immunotherapy News Articles
Cancer Immunotherapy: Immune Suppression and Tumor Growth

Cancer Immunotherapy: Immune Suppression and Tumor Growth
by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor)

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait...

Recombinant Antibodies for Immunotherapy

Recombinant Antibodies for Immunotherapy
by Melvyn Little PhD (Editor)

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, "arming" mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field,...

Immunotherapy of Cancer (Cancer Drug Discovery and Development)

Immunotherapy of Cancer (Cancer Drug Discovery and Development)
by Mary L. Disis (Editor)

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully...

Carbohydrate-Based Vaccines and Immunotherapies (Wiley Series in Drug Discovery and Development)

Carbohydrate-Based Vaccines and Immunotherapies (Wiley Series in Drug Discovery and Development)
by Zhongwu Guo (Author), Geert-Jan Boons (Author)

The fundamental science and the latest developments in carbohydrate-based vaccines

The relatively new field of glycoimmunology has emerged from the marriage of glycobiology and immunology, in recognition of the important role carbohydrates play as antigenic determinants. Carbohydrate-Based Vaccines and Immunotherapies comprehensively reviews the state of this exciting field, offering a single source for both the fundamental science and the latest developments.

With contributions by leading experts, this resource covers the design, synthesis, evaluation, and applications of various carbohydrate-based vaccines, including polysaccharides, neoglycoproteins, and neoglycolipids. The text approaches vaccine design from a chemical and molecular focus, staying in line with...

Allergens and Allergen Immunotherapy, Fourth Edition (Clinical Allergy and Immunology)

Allergens and Allergen Immunotherapy, Fourth Edition (Clinical Allergy and Immunology)
by Richard F. Lockey (Editor), Dennis K. Ledford (Editor)

Modernized and updated, Allergens and Allergen Immunotherapy, Fourth Edition discusses all major areas of allergens and immunotherapies:



pollens
animal/insect
fungi
food
the manufacture and standardization of allergen vaccines
the administration of vaccines
the avoidance and treatment of adverse effects


Compiling the research of an influential team of investigators and scientists, Allergens and Allergen Immunotherapy is filled with quick reference charts, tables and indexes. Allergists, immunologists, and otolaryngologists will find this new streamlined fourth edition a great practical reference for on-the-go diagnosis, treatment, and management of allergies.



NEW TO THE FOURTH EDITION:



new focus on the most...

The Low Dose Immunotherapy Handbook: Recipes and Lifestlye Advice for Patients on LDA and EPD Treatment

The Low Dose Immunotherapy Handbook: Recipes and Lifestlye Advice for Patients on LDA and EPD Treatment
by Nicolette, M Dumke (Author)

The Low Dose Immunotherapy Handbook: Recipes and Lifestyle Tips for Patients on LDA and EPD Treatment gives 80 recipes for patients on low dose immunotherapy treatment for their food allergies. These recipes are for the basic shot time (EPD) diet and the very mixed diet, and include baked goods, main dishes, and side dishes as well as allowable snacks, desserts and treats that make these diets more livable. It also includes organizational information to help you get ready for your shots and sources of special foods and products that low dose immunotherapy patients need.

  Using the Immune System to Treat Cancer



Cancer Stem Cells, Immunotherapy: An Intergrated Approach to Cancer Treatment

Cancer Stem Cells, Immunotherapy: An Intergrated Approach to Cancer Treatment
by Obdulio Piloto (Author)

Our knowledge of cancer initiation, progression and treatment has dramatically increased over the last decade. This understanding promises to deliver novel therapeutic agents that will eliminate the burden of the disease on individuals, families and society. However, early impressive clinical results are often overshadowed by relapse and the development of resistance. Recent studies strongly support the notion that at least some cancers are initiated, maintained and disseminated by cancer stem cells. These cells possess properties of normal stem cells and are typically less responsive to current therapies, thus explaining the observed resistance. Based on the cancer stem cell theory, the elimination of these cancer stem cells is imperative if we are to...

  Immunotherapy of Cancer, An Issue of Hematology/Oncology Clinics (The Clinics: Internal Medicine)
by M. Dhodapka (Author)

Tremendous advances in the understanding the biology of the immune system have ushered in several new approaches to harness the capacity of the immune system in the clinic to both treat and prevent human cancer. Biologics such as monoclonal antibodies now represent the biggest class of newly approved therapies for human cancer, while several vaccine based approaches (including DNA, dendritic cell and peptide vaccines) are also showing promise. In this issue we have brought together several thought leaders in this rapidly advancing field to present the biologic basis, current status as well as near future of immunologic approaches against human cancer.

  PEPTIDE IMMUNOTHERAPY - COLOSTRUM, A PHYSICIAN'S REFERENCE GUIDE
by Andrew M., PhD Keech (Author)



© 2009 BrightSurf.com